• Myth: If a person with haemophilia gets a cut, he’ll bleed to death.

Highly  unlikely. People with haemophilia do not bleed any faster or harder than those without the disease, they simply bleed for longer.

​

• Myth: Haemophilia affects only boys.

While most people assume haemophilia only affects boys, occasionally girls who are “silent carriers” can suffer bleeding symptoms as well. Though extremely rare, a daughter who is born to a father with haemophilia and a mother who is a carrier can actually inherit the severe form of the disease.

​

• Myth: Everyone with haemophilia has the same level of deficiency.

Nope. Depending upon the specific genetic change or mutation in a given family, the severity of the deficiency or level of clotting factor in the blood varies from a severe deficiency to moderate to more mild forms of the disease.

​

• Myth: All forms of haemophilia involve a deficiency in clotting factor VIII.

Not true. Haemophilia A (also known as Classical Haemophilia and Factor VIII Deficiency Haemophilia)  is the most common and is a deficiency in clotting factor VIII. However, Haemophilia B (aka Christmas Disease and Factor IX Deficiency Haemophilia) is—you guessed it—a deficiency in factor IX. Haemophilia C occurs from a lack in factor XI.

​

• Myth: Patients with haemophilia always have a family history of the disease.

A very important false, The gene defect responsible for haemophilia has oneof the highest rates of spontaneous brand new mutations of any human genetic disorder. Some researchers estimate that as many as one-third of the cases of haemophilia are new mutations with no family history of the disease.

​

• Myth: It’s ok to wait until one sees something and really knows it’s a bleed before acting.

Act immediately because especially in brain trauma it can be life and death, When in doubt, treat and then get it checked out.

Haemophilia is a congenital hemorrhagic disease caused by genetic abnormalities in coagulation factor VIII or factor IX. Current conventional therapy to prevent bleeding requires frequent intravenous injections of coagulation factor concentrates from early childhood. Accordingly, gene therapy for haemophilia remains an exciting future prospect for patients and their families, due to its potential to cure the disease through a one-time treatment. After a series of successes in basic research, recent clinical trials have demonstrated clear efficacy of gene therapy for haemophilia using adeno-associated virus (AAV) vectors. Although this is likely to alter the paradigm of haemophilia care in the near future, it will be important to overcome immune responses against AAV. Gene therapy for haemophilia cannot be given to patients with anti-AAV capsid-neutralizing antibodies, and cellular immunity with CD8+ T cells should be controlled for sustained expression. Furthermore, long-term therapeutic effects should be closely observed because of the failure of the AAV vector genome to replicate during cell division.

There is no way to cure hemophilia, but there are ways to reduce the risk of excessive bleeding and to protect joints. These include: regular exercise,  avoiding certain medications, such as aspirin, nonsteroidal anti-inflammatory drugs, and heparin, which are blood thinners,  practicing good dental hygiene. We can provide awareness for the patients. Help them to build self esteem through different activities, strengthen their mental ability, remind them about  regular check up etc.